EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 365 participants.
Also called NCT02816736
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 365 participants
- Registry
-
NCT02816736
-
- Other papers using this trial's data
- Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02816736. Randomized; triple masking; primary purpose treatment. Start 2017-03-02 (actual); primary completion 2020-09-15 (actual). Results posted on 2021-12-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
- Acronym
- HFN-LIFE
- Condition
- Heart Failure
- Intervention (Drug)
- LCZ696
- Intervention (Drug)
- valsartan
- Intervention (Drug)
- LCZ696 placebo
- Intervention (Drug)
- valsartan placebo
- Lead sponsor
- Duke University
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct02816736- Content hash
53118fd7d80c6d507091c4e67aa858c77524a758b3d0c7ed5fae742861b8187a